^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + avadomide (CC-122) (Cereblon modulator, Pleiotropic pathway modifier) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
Published date:
02/14/2022
Excerpt:
In patients with DLBCL, overall response rate (ORR) was 40.7% and median duration of response (mDOR) was 8.0 months. In patients with FL, ORR was 80.5% and mDOR was 27.6 months; response rates were similar in lenalidomide-naïve and -treated patients. Avadomide plus rituximab was well tolerated..
DOI:
https://doi.org/10.1002/jha2.394
